131 related articles for article (PubMed ID: 38452297)
1. Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study.
Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Magnussen B; Dreyer L
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38452297
[TBL] [Abstract][Full Text] [Related]
2. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register.
Frisell T; Dehlin M; Di Giuseppe D; Feltelius N; Turesson C; Askling J;
Rheumatology (Oxford); 2019 Jan; ():. PubMed ID: 30668875
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
5. Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M; Venerito V; Bugatti S; Bazzani C; Biggioggero M; Petricca L; Foti R; Bortoluzzi A; Balduzzi S; Visalli E; Frediani B; Manfredi A; Gremese E; Favalli E; Iannone F; Ferraccioli G; Lapadula G;
Clin Rheumatol; 2021 Oct; 40(10):4039-4047. PubMed ID: 33881676
[TBL] [Abstract][Full Text] [Related]
6. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
[TBL] [Abstract][Full Text] [Related]
7. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
8. Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis.
Pugliesi A; de Oliveira AB; Oliveira AB; Xavier R; da Mota LMH; Bertolo MB; Gonzalez-Gay MA; Citera G; de Carvalho LSF
Adv Rheumatol; 2023 Jul; 63(1):30. PubMed ID: 37415193
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
Barbulescu A; Delcoigne B; Askling J; Frisell T
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
[TBL] [Abstract][Full Text] [Related]
10. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Hetland ML
Rheumatology (Oxford); 2020 Aug; 59(8):1949-1956. PubMed ID: 31764977
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
12. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
13. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
14. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting.
Choi S; Ghang B; Jeong S; Choi D; Lee JS; Park SM; Lee EY
Semin Arthritis Rheum; 2021 Aug; 51(4):685-691. PubMed ID: 34139521
[TBL] [Abstract][Full Text] [Related]
15. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
[TBL] [Abstract][Full Text] [Related]
17. Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs.
Ozen G; Pedro S; England BR; Mehta B; Wolfe F; Michaud K
ACR Open Rheumatol; 2019 Sep; 1(7):424-432. PubMed ID: 31777822
[TBL] [Abstract][Full Text] [Related]
18. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
Grøn KL; Arkema EV; Glintborg B; Mehnert F; Østergaard M; Dreyer L; Nørgaard M; Krogh NS; Askling J; Hetland ML;
Ann Rheum Dis; 2019 Mar; 78(3):320-327. PubMed ID: 30612115
[TBL] [Abstract][Full Text] [Related]
19. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies.
Xie W; Yang X; Huang H; Gao D; Ji L; Zhang Z
Semin Arthritis Rheum; 2020 Oct; 50(5):930-937. PubMed ID: 32906027
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]